FirmaIQ
Org.nr 985 889 635 2007 → 2008 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2008 vs 2007

Shrank 100% on revenue, weaker earnings, cash halved-plus

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2008 with 2007 for LYTIX BIOPHARMA ASA. Revenue 231.7k NOK → 300 NOK (-99.9%). Net result -15.16m NOK → -34.29m NOK. Equity 48.42m NOK → 83.48m NOK.

On the constructive side: equity strengthened; owners injected capital. Pressures included: revenue fell; operating result weakened; net result weakened.

Also worth watching: sharp cash drawdown. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.

At a glance

Scorecard

Revenue
231.7k NOK 300 NOK
-99.9%
Operating result
-15.45m NOK -36.75m NOK
-137.9%
Net result
-15.16m NOK -34.29m NOK
-126.2%
Equity
48.42m NOK 83.48m NOK
+72.4%
Cash
48.20m NOK 16.44m NOK
-65.9%
Total assets
54.96m NOK 94.00m NOK
+71.0%

What improved

  • ↑

    Equity strengthened

    Book equity 48.42m NOK → 83.48m NOK (equity ratio 88.1% → 88.8%). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 48.42m NOK → 83.48m NOK (+35.06m NOK). Reported fact

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 231.7k NOK to 300 NOK (-99.9% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result -15.45m NOK → -36.75m NOK (op. margin -6668.8% → -12249104.0%). Calculated

  • ↓

    Net result weakened

    Net result -15.16m NOK → -34.29m NOK (net margin -6545.5% → -11430940.7%). Calculated

  • ↓

    Cash fell

    Bank deposits 48.20m NOK → 16.44m NOK (-65.9% YoY). Calculated

Things to notice

  • ·

    Sharp cash drawdown

    Cash fell by more than 60% YoY (48.20m NOK → 16.44m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation